Pulmonary & Respiratory Medicine

Joseph-Leon Aumann

Publications

• Research Article
  The 24 Hour Lung Function Time Profile of Olodaterol Once Daily Versus Placebo and Tiotropium in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  Author(s): Peter Lange, Joseph-Leon Aumann, Alan Hamilton, Kay Tetzlaff, Naitee Ting and Eric DeromPeter Lange, Joseph-Leon Aumann, Alan Hamilton, Kay Tetzlaff, Naitee Ting and Eric Derom
  
  Background: Olodaterol is a once-daily long-acting β2-agonist being investigated for the treatment of chronic obstructive pulmonary disease, with ≥ 24 hour bronchodilator activity. Methods: Two replicate, randomized, double-blind, four-way crossover (6-week treatment periods), active (tiotropium 18 μg via HandiHaler®)- and placebo-controlled trials were conducted to evaluate the 24 hour forced expiratory volume in 1 second (FEV1) profile of olodaterol (5 and 10 μg) once daily (via Respimat®). Patients continued with inhaled corticosteroids and xanthines. Spirometry was performed at baseline and over the entire 24 hour post-dose period at week 6 of each treatment phase. Co-primary end points were change from study baseline (response) in FEV1 area under the curve from 0–12 hours (AUC0–12) and FEV1 AUC from 12–24 hours (AUC12– 24); ke.. Read More»
  DOI: 10.4172/2161-105X.1000196

  Abstract PDF